WuXi PharmaTech (Cayman) Inc.
DelistedCIK 1403132fmd_1PTQ850TE2DMMX1ESVYRSDAPVSManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Dec 31, 2014, 7 periods
| Line item | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 |
|---|---|---|---|---|---|---|---|
| Cost of revenue | 157 | 162 | 206 | 251 | 317 | 367 | 423 |
| Gross profit | 96 | 108 | 128 | 156 | 183 | 212 | 252 |
| Realized investment gains (losses) | – | – | – | – | (1) | (4) | 13 |
| Research and development | – | – | 0 | 5 | 8 | 11 | 21 |
| Selling, general and administrative | 57 | 56 | 56 | 67 | 86 | 95 | 127 |
| Total operating expenses | 117 | 56 | 56 | 73 | 94 | 106 | 148 |
| Operating income | (21) | 52 | 71 | 84 | 89 | 105 | 104 |
| Interest expense | 1 | 1 | 0 | 1 | 2 | 2 | 3 |
| Interest and investment income | 2 | 1 | 2 | 6 | 8 | 11 | 19 |
| Other non-operating income (expense) | 1 | 7 | 28 | 9 | 9 | 27 | 3 |
| Income before taxes | (19) | 59 | 101 | 98 | 104 | 138 | 137 |
| Income tax expense | (4) | 6 | 10 | 17 | 17 | 23 | 24 |
| Net income from continuing operations | (15) | 53 | 91 | 81 | 87 | 115 | 112 |
| Net income | (64) | 53 | 91 | 81 | 87 | 115 | 112 |
| Net income to common shareholders | (64) | 53 | 91 | 81 | – | – | – |